Davies B H
Asthma and Allergy Unit, Sully Hospital, South Glamorgan, Wales, United Kingdom.
Clin Ther. 1991 Jan-Feb;13(1):87-91.
The prophylactic effectiveness of the new, second-generation antihistamines cetirizine and terfenadine was evaluated in a double-blind, multicenter study of 487 patients with seasonal allergic rhinitis. The patients were randomly assigned to eight weeks of treatment with 10 mg of cetirizine given either in the morning or evening, or 60 mg of terfenadine twice daily. Success rates in the three treatment groups, as assessed by physicians, were 61%, 58%, and 56%, respectively. On a scale of 0 (no symptoms) to 100 (most severe symptoms), symptoms in the three regimens were rated by patients as 31, 34, and 41, respectively. A significantly greater alleviation of eye watering and irritation was noted in the morning cetirizine group than in the terfenadine group. No serious side effects were experienced. It is concluded that 10 mg of cetirizine once daily is as effective as 60 mg of terfenadine twice daily in the prophylactic treatment of seasonal allergic rhinitis.
在一项针对487例季节性变应性鼻炎患者的双盲、多中心研究中,评估了新一代抗组胺药西替利嗪和特非那定的预防效果。患者被随机分配接受为期8周的治疗,其中一组为每天早晨或晚上服用10毫克西替利嗪,另一组为每天两次服用60毫克特非那定。经医生评估,三个治疗组的成功率分别为61%、58%和56%。在0(无症状)至100(最严重症状)的评分量表上,患者对三种治疗方案症状的评分分别为31、34和41。早晨服用西替利嗪组的流泪和眼刺激症状缓解程度明显大于特非那定组。未出现严重副作用。得出的结论是,在季节性变应性鼻炎的预防性治疗中,每天服用一次10毫克西替利嗪与每天两次服用60毫克特非那定效果相当。